Adherence to treatment guidelines: the association between stroke risk stratified comparing CHADS and CHADS-VASc score levels and warfarin prescription for adult patients with atrial fibrillation by unknown
RESEARCH ARTICLE Open Access
Adherence to treatment guidelines: the
association between stroke risk stratified
comparing CHADS2 and CHA2DS2-VASc
score levels and warfarin prescription for
adult patients with atrial fibrillation
Scott A. Chapman1, Catherine A. St Hill1, Meg M. Little2, Michael T. Swanoski2, Shellina R. Scheiner1,
Kenric B. Ware3 and M. Nawal Lutfiyya2,4*
Abstract
Background: Ischemic stroke is a risk associated with atrial fibrillation (AF) and is estimated to occur five times more
often in afflicted patients than in those without AF. Anti-thrombotic therapy is recommended for the prevention of
ischemic stroke. Risk stratification tools, such as the CHADS2, and more recently the CHA2DS2-VASc, for predicting stroke
in patients with AF have been developed to determine the level of stroke risk and assist clinicians in the selection of
antithrombotic therapy. Warfarin, for stroke prevention in AF, is the most commonly prescribed anticoagulant in North
America. The purpose of this study was to examine the utility of using the CHADS2 score levels (low and high) in contrast
to the CHA2DS2-VASc when examining the outcome of warfarin prescriptions for adult patients with AF. The CHA2DS2-
VASc tool was not widely used in 2010, when the data analyzed were collected. It has only been since 2014 that
CHA2DS2-VASc criteria has been recommended to guide anticoagulant treatment in updated AF treatment guidelines.
Methods: Bivariate and multivariate data analysis strategies were used to analyze 2010 National Ambulatory Care Survey
(NAMCS) data. NAMCS is designed to collect data on the use and provision of ambulatory care services nationwide. The
study population for this research was US adults with a diagnosis of AF. Warfarin prescription was the dependent variable
for this study. The study population was 7,669,844 AF patients.
Results: Bivariate analysis revealed that of those AF patients with a high CHADS2 score, 25.1% had received a warfarin
prescription and 18.8 for those with a high CHA2DS2-VASc score. Logistic regression analysis yielded that patients with AF
had higher odds of having a warfarin prescription if they had a high CHADS2 score, were Caucasian, lived in a zip code
where < 20% of the population had a university education, and lived in a zip code where < 10% of the population were
living in households with incomes below the federal poverty level. Further, the analysis yielded that patients with AF had
lesser odds of having a warfarin prescription if they were≥ 65 years of age, female, or had health insurance.
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Conclusions: Overall, warfarin appears to be under-prescribed for patients with AF regardless of the risk
stratification system used. Based on the key findings of our study opportunities for interventions are present
to improve guideline adherence in alignment with risk stratification for stroke prevention. Interprofessional
health care teams can provide improved medical management of stroke prevention for patients with AF.
These interprofessional health care teams should be constituted of primary care providers (physicians,
physician assistants, and nurse practitioners), nurses (RN, LPN), and pharmacists (PharmD, RPh).
Keywords: Warfarin, CHADS2, CHA2DS2-VASc, Atrial fibrillation, Stroke, Guideline Adherence, Anti-coagulation,
Interprofessional health care teams
Background
Atrial fibrillation (AF), the most common sustained form
of cardiac arrhythmia, is characterized by disorganized
electrical activity in the atria accompanied by an irregular
ventricular response that is usually rapid [1]. In 2010,
there were 1.2 million new diagnoses of AF in the United
States (US). During that same year, the prevalence of AF
was estimated at 5.2 million in the US, and projected to
increase to 12.1 million individuals by 2030 [2]. AF is an
age prevalent condition. Estimates of the prevalence range
from 0.1% of individuals less than 55 years of age to 9.0%
of individuals over 80 years of age, with 3.8% of individuals
60 years and older having AF [3].
Stroke poses a significant health burden in the US and
therefore prevention is warranted. In addition to the
years of life lost (mortality) and disability (morbidity) the
direct and indirect costs of stroke as part of the disease
burden are considerable [4–7]. The projected total esti-
mated cost of stroke will be at least $300 billion or more
by 2050 [8, 9].
This significant cost for stroke underscores the im-
portance of stroke prevention efforts. Treatment also
contributes to the cost burden of stroke. Casciano, et al.,
[10] using prescription claims data as a proxy for pre-
scription adherence, examined the cost burden associ-
ated with sub-optimal warfarin treatment and found that
healthcare costs (fewer inpatient and hospital visits, and
hospital days) were 13% lower for people with AF who
were prescribed warfarin and were taking the drug.
Ischemic stroke is an important risk associated with AF
and is estimated to occur five times more often in afflicted
patients than those without AF [4]. Fifteen percent of all
strokes are associated with AF [5]. Because of this risk, an-
tithrombotic therapy is recommended for the prevention
of ischemic stroke. In a pooled analysis of five randomized
controlled trials evaluating stroke risk and antithrombotic
therapy, the average stroke rate in patients not receiving
antithrombotic therapy was found to be 4.5% per year [6].
Patients with AF who suffer stroke have an increased risk
for: increased stroke severity, 30 day mortality, and higher
rates of 1 year recurrence of stroke compared to stroke
sufferers without AF [7].
Risk stratification tools for predicting stroke in pa-
tients with AF have been developed to determine the
level of stroke risk and assist clinicians in the selection
of antithrombotic therapy. The risk of stroke (reported
as an adjusted stroke rate per 100 person years) is 1.9
(95% CI, 1.2–3.0) for a CHADS2 score of 0, and in-
creases to 18.2 (95% CI, 10.5–27.4) for a CHADS2 score
of 6 [11]. The CHA2DS2-VASc score was established in
2010 [12] as a refinement over the CHADS2 score in the
predictive value of stroke [13]. Even though CHA2DS2-
VASc was not used widely at the time the data were col-
lected, we examined CHA2DS2-VASc criteria in relation
to our data. We compared CHADS2 to CHA2DS2-VASc
as the latter is now recommended in the AF treatment
guidelines updated in 2014.
Although, in October 2010, dabigatran was approved by
the FDA as the first non-vitamin K antagonist oral anti-
coagulant for prescription in the US, warfarin was approved
much earlier in 1954 and remains the most commonly pre-
scribed anticoagulant in North America, including its use
for stroke prevention in AF [14, 15]. A meta-analysis in-
cluding six trials comparing warfarin to placebo or no treat-
ment, found that warfarin reduced ischemic stroke events
by 67% [16]. Comparing CHADS2 and CHA2DS2-VASc as
risk stratification strategies is an important consideration in
prescribing warfarin therapy. CHA2DS2-VASc in contrast
to CHADS2 more accurately identifies patients at low risk
for ischemic stroke and moves more patients from the
intermediate level to the high risk level. The importance
should not be underestimated since doing so reduces the
ambiguity of identifying those patients who actually need
anti-thrombotic therapy [17].
Studies in the US examining patterns in anticoagula-
tion for AF have shown an increase in the overall trend
of warfarin use in the past several years [18–20]. Yet,
warfarin appears to be under-prescribed [21, 22]. To as-
sess the prescription patterns for warfarin as determined
by CHAD2 versus CHA2DS2-VASc criteria, we analyzed
data from the 2010 NAMCS, a large publically available
database of patient records that are weighted to be rep-
resentative of the US population. The large sample size
and weighted data allow for generalizable results. At
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least one earlier study from 1996 [23] also examined
NAMCS data. However, those data from multiple years,
are decades old and were collected before either
CHADS2 or CHA2DS2-VASc were developed. The pur-
pose of this study was to examine the association be-
tween CHADS2 score levels (low and high) and warfarin
prescriptions for adult patients with AF. We evaluated
the prevalence of adherence to antithrombotic therapy
for AF treatment guidelines that were in place when the
data were collected [24] and compared these to the de-
scriptive results of using the CHA2DS2-VASc system for
risk assessment.
Methods
Both bivariate and multivariate analytic approaches were
used to examine 2010 NAMCS data in order to answer
the research question. The NAMCS was designed and is
used to collect data on the actual use and provision of am-
bulatory care services throughout the US. A national sam-
ple of ambulatory care visits are surveyed in order to
collect the data. A complex four-stage probability sam-
pling design is employed in the data collection process. A
description of the sampling strategy is discussed elsewhere
[25]. Because they were the most recently available data at
the onset of this study, the 2010 NAMCS data were used.
These data are weighted, by the survey designers, to be
nationally representative of patient health records.
As recommended by the Center for Disease Control
and Prevention’s (CDC) National Center for Health Statis-
tics (NCHS), all analyses were performed on weighted
data. The weighting, as calculated, uses the most recently
available census data to provide a stratified representation
of the nation’s primary care patient population. Only
weighted data are reported in the results.
The Patient Record Form is the survey instrument for
data abstraction from the medical record. The NAMCS pa-
tient record form is completed by ambulatory care clinic
staff for a systematic random sample of patient visits during
a randomly assigned 1-week reporting period. The data ob-
tained include demographic characteristics of patients,
expected source(s) of payment, patients’ complaints, diag-
noses, diagnostic/screening services, procedures, medica-
tion therapy, disposition, types of providers seen, causes of
injury, and certain characteristics of the clinic facility, such
as geographic region and metropolitan status.
For this research project, the study population was US
adults with a diagnosis of AF. The ICD-9 code for AF is
427.31. The covariates or independent variables for this
research were: CHADS2 score levels (low and high), sex
(male/female), race (Caucasian/Non-Caucasian), geo-
graphic locale (rural/non-rural), education attainment in a
patient’s zip code (<20% of adults with a university de-
gree/≥ 20% of adults with a university degree), poverty
level in patient’s zip code (<10%/≥ 10%), health insurance
status (insured/noninsured), and primary health care pro-
vider (HCP) seen (yes/no). Patient age was also a covariate
in this study. For some of the analyses performed,
CHADS2 age ranges are reported (<75 years/≥75 years), in
other analyses three age-ranges were included (18–39,
40–64, and ≥ 65). For the logistic regression analysis per-
formed the two age ranges used were 40–64 years and ≥
65 years. All of the study covariates were recoded from
their original configuration for analyses. Re-coding
entailed either collapsing categories and/or removing un-
known responses.
CHADS2, one of the study covariates or independent var-
iables, is a clinical prediction tool for estimating the risk of
stroke for patients with non-valvular AF. AF is associated
with thromboembolic stroke. A CHADS2 score ranges from
0 to 6 and is computed from the following variables: con-
gestive heart failure (1 point), hypertension (1 point), age
≥75 years (1 point), diabetes (1 point), and prior stroke or
transient ischemic attack (TIA) (2 points). Patients with a
score ranging from 0 to 1 were coded as having a low
CHADS2 score and those with a score ≥ 2 were coded as
having a high CHADS2 score. The stroke/TIA variable was
computed from six, three digit ICD-9 codes for stroke
(434.00, 434.01, 434.10, 434.11, 434.90, 434.91) and six,
three digit ICD-9 codes for TIA (435.0, 435.1, 435.2, 435.3,
435.8, 435.9). Those patients with any of the 12 possible
conditions were coded as 1 and those without any of the
conditions were coded as 0. In contrast, the CHA2DS2-
VASc includes the additional criteria: 2 points for age
≥75 years, 1 point for vascular disease (previous MI, periph-
eral artery disease, aortic plaque), 1 point for female sex,
and 1 point for ages 65 to 74 years. CHA2DS2-VASc scores
range from 0 to 9. Scores ≥2 points were considered to be
high risk and 0 was considered a low risk for stroke.
The findings from an earlier study comparing the
newer CHA2DS2-VASc to the older CHADS2 [13] found
no statistically significant differences between the risk
stratification results for different population groups and
the associated warfarin prescribing patterns. Further,
Odum, et al., [17] noted that the implementation of this
risk schema warrants further and continual assessment.
With these considerations in mind, we examined differ-
ences in prescribing patterns and risk stratification com-
paring both tools.
Warfarin prescription was the dependent variable for this
study. Using the CDC’s New Ambulatory Care Drug Data-
base System for NAMCS data, prescribed drugs were clas-
sified as warfarin or other. Six separate drugs were re-
coded as the variable warfarin. These were: Jantoven,
Athrombin K, Coumadin, Panwarfin, Warcef, and warfarin.
In order to identify patients at risk for bleeding, the
three digit ICD-9 codes associated with GI hemorrhage
were merged into a variable called bleed risk. All patients
with a risk for GI bleeding were excluded from the study.
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Statistical Package for Social Scientists (SPSS, IBM,
Chicago, IL, version 23.0) was used to complete all statis-
tical analyses and alpha was set at p ≤ 0.05. Bivariate contin-
gency table analysis was conducted to establish the
relationships between each of the covariates and the
dependent variable. Bivariate analysis tests whether or not a
statistically significant relationship exists between an out-
come or dependent variable and a predictor or independent
variable. Bivariate analysis is not a stratified analysis. A chi
square was computed as the test statistic for differences be-
tween percentages. Multivariate logistic regression analysis,
to produce adjusted measures and eliminate confounding,
was also performed using SPSS (version 23.0).
The Institutional Review Board (IRB) at the re-
searchers’ institutions recognize that the analysis of de-
identified and publicly available data does not constitute
human subjects research as defined in federal regula-
tions and as such does not require IRB review. Hence,
human subjects’ approval was not necessary nor sought
since this was a de-identified data only study.
Results
The study population was 7,669,844 adult AF patients.
Table 1 displays the characteristics of US adults with AF.
Of note, this population is more male than female, Cauca-
sian than non-Caucasian, university graduates, and almost
evenly divided by percent poverty in neighborhood. In
terms of individual variables used to calculate the
CHADS2 score, in order, hypertension was the most
prevalent followed by age ≥ 75, diabetes, and congestive
heart failure. The variable contributing the least to the
CHADS2 score was history of stroke. Twelve percent of
the population was at minimal risk for stroke, 35% was at
moderate stroke risk, and 53% was at high stroke risk.
Table 2 displays the results of a bivariate analysis that ex-
amined the relationship between each independent covari-
ate by warfarin prescription status (yes or no) for patients
with AF. The differences for warfarin prescription status by
each of the covariates were statistically significant. Most
notably, of those AF patients with a high CHADS2 score,
25.1% had received a warfarin prescription from their HCP.
Table 3 displays the analysis conducted examining
CHADS2 score by age range of patients with AF by
whether or not the patient had a prescription for war-
farin. For patients with a low CHADS2 score, 12.4% of
those 40 – 64 years of age and 8.4% ≥ 65 years had a pre-
scription for warfarin. For those patients with a high
CHADS2 score, 33.0% of those 40 – 64 years of age and
24.6% ≥ 65 years had a prescription for warfarin.
Table 4 displays the findings from the logistic regression
analysis performed using having a warfarin prescription as
the dependent variable. Seven covariates were entered into
the model. The analysis yielded that patients with AF who
were ≥ 40 years of age had higher odds of having a warfarin
prescription if they had a high CHADS2 score, were Cauca-
sian, lived in a zip code where < 20% of the population had
a university education, and lived in a zip code where < 10%
of the population were living in households with incomes
below the federal poverty level. Further, the analysis yielded
that patients with AF who were ≥ 40 years of age had lesser
odds of having a warfarin prescription if they were ≥
65 years of age, female, or had health insurance.
Table 1 AFIB Population Description 2010 NAMCS Data (weighted
n= 7,669,844)
Variable Factor Frequency Percent
Sex Female 3548521 46.3
Male 4121323 53.7
Health Insurance Status Have Health Insurance 7428685 96.9
Do Not Have Health
Insurance
241159 3.1
Race Caucasian 6571700 85.7
Non-Caucasian 1098144 14.3












Geographic Locale Rural 1288012 16.8
Non-Rural 6205257 80.9
Unknown 176575 2.3
Primary HCP Yes 3128743 40.8
No 4095339 53.4
Unknown 445762 5.8
Warfarin No 6297368 82.1
Yes 1372476 17.9
Congestive Heart Failure No 6584055 85.8
Yes 1085789 14.2
Diabetes No 5942040 77.5
Yes 1727804 22.5
Hypertension No 2512157 32.8
Yes 5157687 67.2
History of Stroke or TIA No 7576285 98.8
Yes 93559 1.2
CHADS Age <75 Years 3544600 46.2
≥75 Years 4125244 53.8
CHADS2 Score
a Low Score 3596112 46 .9
High Score 4073732 53.1
aTo calculate a CHADS2 score 1 point is assigned to each of the variables:
congestive heart failure, hypertension, ≥75 years, diabetes, and 2 points for
history of stroke or TIA
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Table 5 displays a comparison of CHADS2 with
CHA2DS2-VASC in terms of percent of AF patient popula-
tion by risk category (high, intermediate, or low) by percent
warfarin prescription and by percent difference for risk cat-
egory and warfarin prescription. The comparison yielded
that the 2010 AF patient population would have a larger
proportion categorized with a high stroke risk (higher by
46.7%) and lower proportions with both intermediate and
low stroke risk (by 112.8 and 86.4% respectively). While
25.1% of high stroke risk AF patients had a warfarin pre-
scription using the CHADS2 criteria, 18.1% (28.7% fewer)
had such when applying the CHA2DS2-VASC criteria.
Discussion
Patients with AF are at higher risk for stroke than pa-
tients in normal sinus rhythm. CHADS2 is a tool devel-
oped to risk-stratify stroke in this patient population [6].
Table 2 Study Covariates by Warfarin Prescription for Adults
with Atrial Fibrillation NAMCS 2010 Data (weighted n = 7669844)
Variables and factors Warfarin prescription
statusa
% Other or No
Medication
% Warfarin

























Geographic Locale Rural 83.3 16.7
Non-Rural 81.6 18.4
Primary HCP Yes 79.7 20.3
No 82.2 17.8
Unknown 98.3 1.7





Hypertension No 91.8 8.2
Yes 77.4 22.6
Age <75 Years 89.7 10.3
≥75 Years 75.6 24.4






CHADS2 Score Low Score (0–1) 92.7 7.3
High Score (2 and
higher)
74.9 25.1
aThe differences for warfarin prescription status by each of the covariates was
statistically significant (p < .05)
Table 3 Warfarin Prescription by Patient Age and CHADS2 Score
Level for Patients with Atrial Fibrillation 2010 NAMCS Data





# % # %
Low Score (0–1) 18–39 80454 100.0 0 0
40–64 1172589 87.6 165537 12.4
≥65 1994254 91.6 183278 8.4
High Score (2 And Higher) 18–39 0 0 0 0
40–64 158286 67.0 77884 33.0
≥65 2891785 75.4 945777 24.6
Total 18–39 80454 100.0 0 0
40–64 1330875 84.5 243421 15.5
≥65 4886039 81.2 1129055 18.8
Table 4 Logistic Regression Model with Dependent Variable
Warfarin Prescription for US Adults ≥40 Years with Atrial Fibrillation












CHADS2 Score Low Score (0–1) –
a
High Score (2 and
Higher)
2.911 (2.906,2.915)
Sex Female .548 (.547,.549)
Male –a
Race Caucasian 2.393 (2.386,2.399)
Non-Caucasian –a
Health Insurance Status Have Health Insurance .817 (.814,.820)
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Our study examined the associations between CHADS2
score levels (low and high) and warfarin prescriptions
for patients with AF in order to ascertain the prevalence
of prescriber adherence to 2008 anti-thrombotic therapy
for AF treatment guidelines. 2010 NAMCS data were
analyzed and a number of notable findings were yielded
from our analyses. The most important findings are dis-
cussed below.
First, our findings suggested that only 25% of those at
highest risk for ischemic stroke were prescribed warfarin.
Earlier findings are mixed on this issue. For instance,
Zimetbaum, et al., [26] examining claims data for adults ≥
18 years, found that there was no difference in the
prevalence of warfarin prescribing by CHADS2 risk level
(approximately 40% by each risk level). Raji, et al., [19]
examining Medicare Part D claims data found that 67.8% of
the highest risk (by CHADS2 score) AF patients had been
prescribed warfarin. Our results are clearly much lower
than these two earlier studies. These other studies exam-
ined different data—claims data versus our medical record
data. These two types of data could, by definition, generate
different denominators. This difference provides a partial
explanation for differences in the prevalence rates identi-
fied. An additional, partial explanation for our findings may
include the necessity of providers balancing the benefits of
appropriate anticoagulation with the risks that are associ-
ated with warfarin [27, 28]. Even though we accounted for
risk of bleeding in our analysis, providers may still have
made prescribing choices based on a presumed risk of
bleeding events such as intracranial hemorrhage, GI bleed-
ing, and subdural hematoma after a fall [29].
Second, our findings indicated that when stratifying by
CHADS2 score, strong associations between age and antic-
oagulation therapy in the form of a prescription for war-
farin were revealed for patients with AF. These prevalence
rates were higher in the younger age group (40 – 64 years)
than the older age group (≥65 years) regardless of CHADS2
score. Other studies have reported similar findings. For in-
stance one study, [29] using clinical administrative data
from Kaiser found that older age (≥85 years) AF patients
had a lower prevalence of warfarin prescription. Yet an-
other study used Get with the Guidelines Program data
from 2001 to 2005. The researchers evaluated warfarin ad-
herence in patients admitted for stroke who had either AF
present on admission or had a history of AF. The results re-
vealed that patients ≥65 years received warfarin less often
than younger patients, and that this ratio did not improve
over time. Furthermore, gender disparities were apparent as
overall, women were less likely to receive warfarin [30].
In agreement with Lewis et al., [30] we found that
women > 40 years of age with AF were less likely to be
prescribed warfarin. Some studies have similar findings
while others have found no gender differences in warfarin
prescribing patterns [31, 32]. For instance, in a Swedish
study [31] examining medical records of men and
women ≥ 45 years of age, no consistent associations be-
tween the CHADS2 score and prescribed warfarin treat-
ment were found. Another study [32] conducted in
Canada found that for patients with AF, older women
(≥75 years) were half as likely to be prescribed warfarin in
comparison to men in the same age group (24.5% vs.
44.9%, p = 0.034). Since our study included women
40 years and older with AF, the population included is
more representative of those at risk for stroke in contrast
to women 75 years and older. Some of the differences be-
tween our findings and those of others may be accounted
for by the wider age inclusion.
Finally, our findings support the claims [17] that when
using the criteria of CHA2DS2-VASc, more AF patients
will be classified at high risk and fewer at intermediate
risk. These changes are significant since the recommenda-
tion for anticoagulant therapy is made clearer, removing a
large proportion of AF patients from the intermediate cat-
egory, leaving the choice of therapy up to the provider.
Based on the key findings of our study, as discussed
above, opportunities for interventions are present to im-
prove guideline adherence in alignment with risk stratifica-
tion for stroke prevention. Interprofessional health care
teams can provide improved medical management of stroke
prevention for patients with AF. These interprofessional
health care teams should be constituted of primary care
providers (physicians, physician assistants, and nurse practi-
tioners), nurses (RN, LPN), and pharmacists (PharmD,
RPh). Health care teams are not a new concept [33–38]
and typically such a team refers to two or more individuals,
each with a specific role, working toward a common goal
with concrete boundaries [35]. Frequently, health care
teams work on complex tasks requiring a coordination of
Table 5 Comparison of CHADS2 and CHADS2VASC2 NAMCS 2010 Data













High Stroke Risk (≥2 points) 53.1 25.1 85.5 18.8 46.7 28.7
Intermediate Stroke Risk (1
point)
34.8 12.2 9.7 19.9 112.8 48.0
Low Stroke Risk (0 points) 12.1 2.5 4.8 1.3 86.4 63.2
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effort [34–38]. In many instances developing a team ap-
proach to this type of care and medical management re-
quires a culture shift in both specific practices as well as
clinical professions [34–39]. A more integrated team care
approach could lead to better guideline adherence and sub-
sequent reduction in actual strokes in patients with AF,
leading to reduced morbidity and health care cost.
Some clinicians [37] have noted that there has been a
“quantum leap” in the complexity of tasks required of
primary care such that physicians alone are no longer able
to cope with the resulting wide scope of practice. This
coupled with the ongoing demand for health care cost
containment [37, 39, 40] has led to the exploration of pri-
mary care teams that include physician assistants and nurse
practitioners. Moreover, a demand for better health care
quality and safety has provided the opportunity for pharma-
cists to be included in primary care teams as health care
givers with beneficial skills that complement those of physi-
cians [37–40]. There is growing evidence, around some
chronic conditions such as diabetes, that interprofessional
health care teams improve patient outcomes and contribute
to contained health care costs [37–40].
Limitations
There are some limitations to our study. For instance, using
NAMCS data did not allow for any analysis that would de-
tect prescriber bias. Furthermore, NAMCS data are not
longitudinal and are only point-in-time single visit data.
Hence, no continuity of care is captured that might provide
an indication of changes over time regarding medication
use or a broader overview of prescribing patterns for indi-
vidual patients. Additionally, only a limited number of diag-
noses are captured on the patient survey hence it is
possible that not all instances of AF were identified. An-
other limitation is that the education status of the patients
with AF were not recorded but instead the percentage of
persons with a university education in the zip code was
used as a proxy. Furthermore, not all contraindications to
warfarin may have been identified. Also, because of the lim-
ited number of medications that can be listed on the patient
data form, warfarin may have been under-reported on the
medication list. Finally, different classifications of AF were
not listed nor was the duration of disease.
Conclusions
This study underscores the importance of a comprehen-
sive assessment of risk factors associated with stroke in
patients with AF and the prescribing of warfarin. This is
especially true for older (those ≥ 65 years), as well as fe-
male patients. Overall, warfarin appears to be under-
prescribed for patients with AF. Given the benefit of
warfarin use for those most at risk for ischemic stroke,
our findings suggest that warfarin should be prescribed
with closer adherence to guideline recommendations.
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